Abstract #2243
MRS changes in diffuse intrinsic pontine gliomas correlate with survival
Stefan Bluml 1,2 and Ashok Panigrahy 3
1
Children's Hospital Los Angeles/USC, Los
Angeles, CA, United States,
2
Rudi
Schulte Research Institute, Santa Barbara, CA, United
States,
3
Children's
Hospital of Pittsburgh/UPMC, Pittsburgh, PA, United
States
Diffuse intrinsic pontine glioma (DIPG) carry the worst
prognosis in pediatric neurooncology, with the majority
of patients dying within six to 18 months after
diagnosis. Due to the lack of tissue samples, small
patient numbers, and the challenges of clinical research
in the pediatric population, there has been no
improvement in outcomes for decades. This study
demonstrates that serial MRS identifies subgroups of
longer survival vs. shorter survival survival at an
early stage of the disease. This finding demonstrates
that MRS could be used to adjust therapies in individual
patients but also to evaluate the effectiveness of new
treatment strategies in a timely fashion.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
